Online inquiry

IVTScrip™ mRNA-Anti-APP, BART(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3520MR)

This product GTTS-WQ3520MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets APP gene. The antibody can be applied in Alzheimer's disease (AD) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000484.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 351
UniProt ID P05067
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-APP, BART(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ3520MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10199MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7, LDP-02(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LDP-02
GTTS-WQ11994MR IVTScrip™ mRNA-Anti-ERBB3, MM-121(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MM-121
GTTS-WQ15478MR IVTScrip™ mRNA-Anti-MAPT, UCB-0107(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA UCB-0107
GTTS-WQ3622MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1179470(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BAY 1179470
GTTS-WQ14200MR IVTScrip™ mRNA-Anti-IL17A, RG4934(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA RG4934
GTTS-WQ14343MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG7716(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA RG7716
GTTS-WQ10583MR IVTScrip™ mRNA-Anti-ANGPT2, LY-3127804(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA LY-3127804
GTTS-WQ7403MR IVTScrip™ mRNA-Anti-EGFR, GA201(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GA201
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW